Non‐steroidal anti‐inflammatory drugs (NSAIDs) and specific inhibitors of cyclooxygenase
(COX)‐2, are therapeutic groups widely used for the treatment of pain, inflammation and …

Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been
associated with reduced risk of colorectal cancer. Moreover, the NSAID sulindac reduces the …

Abstract Cyclooxygenase‐2 (COX‐2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers. A …

Background Epidemiologic and laboratory investigations suggest that aspirin and other
nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against colon …

There is strong evidence for an important role for increased COX (cyclo-oxygenase)-2
expression and PG (prostaglandin) E2 production in colorectal tumorigenesis. PGE2 acts …

In addition to the well-established pathophysiological role that COX-2 plays in inflammation,
recent evidence implies that this isoform may also be involved in multiple biologic events …

Significant use of selective cyclooxygenase-2 (COX-2) blocking agents prescribed for the
treatment of arthritis during 1999 to 2005 facilitates epidemiologic investigations to …

Cyclooxygenase-2 (COX-2) is the enzyme primarily responsible for prostaglandin synthesis
in the setting of inflammation. It also can be induced by a variety of agents, including tumor …

Mortality in patients with advanced colorectal cancer (CRC) remains high. Epidemiologic
studies show that individuals taking nonselective, nonsteroidal anti-inflammatory drugs …

Epidemiological, clinical and animal studies indicate non-steroidal anti-inflammatory drugs
(NSAIDs) to be chemopreventive for colorectal cancer. The best established target for …